News Coverage 06.08.22 Share on Twitter Share on Facebook Share on LinkedIn Why these cancer immunotherapy experts are leaning into a five-year deal Related Announcement, Partner Highlight, Press Release Alliance Aims to Develop Next-Gen Cancer Therapies Announcement Parker Institute for Cancer Immunotherapy Announces Appointment of Mark Veich as Chief Organizational Advancement Officer Announcement, Press Release Parker Institute for Cancer Immunotherapy Demonstrates Leadership and Showcases Latest Advances in Immunotherapy at SITC 2025 Annual Meeting
Announcement Parker Institute for Cancer Immunotherapy Announces Appointment of Mark Veich as Chief Organizational Advancement Officer
Announcement, Press Release Parker Institute for Cancer Immunotherapy Demonstrates Leadership and Showcases Latest Advances in Immunotherapy at SITC 2025 Annual Meeting